Oncologica®’s Immunofocus Solutions
Immunofocus TMB Test assesses the number of mutations (and the related number of neoantigens) in the cancer cell. The higher the tumour mutational burden, the higher the chance for the individual to respond to Immunotherapy.
1. Multiple DNA mutations occur in the tumour cell
2. Mutations create neoantigens which are recognised for targeted killing by immune system
3. Immunotherapy activates the immune cells to target the neoantigens and kill the tumour cell
Tumour mutational burden (TMB) is a biomarker test for multiple disease types that together with Oncofocus DNA tests provide truly comprehensive tumour sample immunotherapy informatics. Faster genetic disease information can speed you to your next steps.
The Immunofocus TMB test is performed on routine biopsy samples to assess the number of DNA mutations in a tumour cell’s genome, which can be used to predict the response to immunotherapy.
Immunofocus PD-L1 Test measures the expression levels of PD-L1 protein which can be used to identify those patients most likely to respond to PD-1/PD-L1 directed immunotherapies.
A range of cancer types have been shown to bind PD-L1 with the PD-1 of immune cells (t-cells). This blocks the activation of the t-cell, allowing the tumour cell to evade destruction. The cancer types effected include:
- head and neck
Targeting the PD-1/PD-L1 connections with inhibitors has emerged as a powerful immunotherapy against these cancer types. Inhibiting the PD-1/PD-L1 pathway with therapeutic antibodies results in restoration of immune responses and activation of t-cells directed to kill the tumour cell.
This therapy has been shown to induce a strong clinical response in many tumour types, for example 20-40% in melanoma and 33-50% in advanced non small cell lung cancer (NSCLC).
Malfunctioning of the Mismatch Repair (MMR) pathway increases the mutational burden of specific cancers and is often involved in the cause of the malfunction, sometimes as an influential bystander and sometimes as the main driving force.
Immunofocus MMR Test analyses the Mismatch Repair genes (MLH1, MSH2, MSH6 and PMS2) to identify DNA repair defects linked to response to immunotherapy. The MMR test quickly identifies whether or not a new class of medicines will benefit you.
The MMR genetic test results provide the data needed to get access to the medicines through your oncologist or a clinical trial as quickly as possible. If the tests show that immunotherapy will benefit you, then the sooner you begin treatment the sooner you can start feeling better.
The Oncofocus® cancer test allows your clinician to accurately identify the best treatment for your cancer.
Oncofocus® may be requested by your hospital, doctor or oncologist. If your doctor is not aware of this test option, our patient consultants can guide you and suggest the best option to present Oncofocus® to your doctor to get an Oncofocus® test in your country.
As a clinician, you will have a powerful tool to optimise therapy choices and improve patient outcomes.
As a clinician you can register and request a test today. If you need more information or have any questions about the Oncofocus® cancer test you can also request a consultation with our Oncologica® Support team.